There is so much CAR T Development happening in Myeloma, it's hard to keep track of it all. One of the sessions discussed relapsed and refractory myeloma strategies and almost all of the discussion centered around CAR T.  Siddhartha Ganguly, MD of the University of Kansas shares the importance of CAR T trials and those [...]